What are the maternal and fetal risks associated with using a Port‑A‑CATH (implanted venous access device) during pregnancy?

Risks of Port-A-Cath During Pregnancy

Port-A-Cath and other central venous access devices carry a 25% overall complication rate during pregnancy, with infectious complications occurring in 12% of cases and mechanical failures, thrombosis, and other serious events making up the remainder.

Maternal Risks

Infectious Complications

• Culture-proven line infection occurs in 12% of central venous catheters placed during pregnancy, representing the single most common complication 1
• Bacteremia requiring intravenous antibiotics occurs in 20.2% of peripherally inserted central catheters (PICCs) during pregnancy, suggesting similar or higher rates may occur with Port-A-Cath systems 2
• Presumed line infections without positive cultures add an additional 2% complication rate 1

Thrombotic Complications

• Superficial and deep venous thrombosis occurs in 2% of central venous catheters during pregnancy 1
• Pregnancy creates a hypercoagulable state that significantly increases the baseline risk of catheter-related thrombosis compared to non-pregnant patients 3
• The risk of thrombosis is particularly elevated with catheters in the upper extremity venous system during the volume-expanded state of pregnancy 1

Mechanical Complications

• Mechanical catheter failure occurs in 4% of cases, including catheter occlusion, malposition, or structural damage 1
• Port-A-Cath occlusion rates of 21.5% have been reported in non-pregnant oncology patients, with higher rates (43.8%) when small-bore catheters are used for continuous infusions 4
• Catheter malfunction requiring removal or replacement occurs more frequently during pregnancy due to increased blood volume and altered coagulation 2

Other Maternal Complications

• Hematoma formation at the insertion site occurs in 2% of cases 1
• Ventricular arrhythmias, though rare (1%), represent a potentially life-threatening complication 1
• Patient discomfort requiring catheter removal occurs in 1% of cases 1

Timing and Risk Factors

Gestational Age Considerations

• 76% of central venous catheters during pregnancy are placed antepartum at a mean gestational age of 24.7 ± 10.7 weeks, when physiologic changes are already substantial 1
• The hypercoagulable state intensifies as pregnancy progresses, increasing thrombotic risk in the second and third trimesters 3

Patient-Specific Risk Factors

• Diabetes significantly increases complication risk (hazard ratio 2.71,95% CI 1.13-6.13) and is the only factor proven to predict complications in pregnant patients with central venous access 2
• The type of infusate (parenteral nutrition versus intravenous fluids alone) does not significantly alter complication rates during pregnancy 2
• Duration of catheter placement does not independently predict complications, though longer dwell times accumulate risk 2

Fetal Risks

Radiation Exposure During Placement

• Fluoroscopy-guided Port-A-Cath placement exposes the fetus to ionizing radiation, which carries risks of malformation and growth restriction 5
• Abdominal and pelvic shielding must be used during any fluoroscopic procedure in pregnancy, and fluoroscopy time should be minimized to less than 2 minutes when possible 5
• Placement after 20 weeks of gestation is preferred when the procedure can be safely delayed, as this timing minimizes teratogenic risk 5

Indirect Fetal Risks from Maternal Complications

• Maternal bacteremia from line infection can lead to preterm labor, premature rupture of membranes, and fetal inflammatory response syndrome 1, 2
• Maternal venous thromboembolism requiring therapeutic anticoagulation increases the risk of placental abruption and fetal hemorrhage 6
• Severe maternal complications requiring surgical intervention or intensive care carry substantial fetal morbidity and mortality risk 1

Overall Risk Profile

Cumulative Complication Rate

• The overall complication rate for central venous catheters during pregnancy is 18.5 per 1000 catheter-days, affecting 55.9% of all catheters placed 2
• Major complications requiring surgical intervention, intravenous antibiotics, or treatment for thromboembolism occur in 22.6% of cases 2
• This complication rate is substantially higher than in non-pregnant populations and occurs in the majority of pregnant women with central venous access 2

Critical Clinical Implications

Indications Must Be Compelling

• Port-A-Cath should be used judiciously and only when clearly necessary during pregnancy, given the high complication rate 2
• Failed peripheral intravenous access alone may not justify the risks unless the clinical need for venous access is urgent and prolonged 1
• Alternative strategies, including ultrasound-guided peripheral IV placement or midline catheters, should be exhausted before proceeding with Port-A-Cath placement 2

Monitoring Requirements

• Pregnant patients with Port-A-Cath require more intensive monitoring than non-pregnant patients, with vigilance for signs of infection, thrombosis, and mechanical failure 1, 2
• Regular assessment of catheter function and insertion site should occur at each prenatal visit 2
• A low threshold for catheter removal should be maintained if complications develop, as conservative management often fails during pregnancy 2

Common Pitfalls to Avoid

• Do not assume that Port-A-Cath complication rates in pregnancy mirror those in non-pregnant patients—the rate is substantially higher and affects the majority of catheters 2
• Do not place a Port-A-Cath for convenience alone—the 25% overall complication rate and 12% infection rate demand a compelling clinical indication 1
• Do not neglect diabetes screening and optimization—diabetes is the only proven predictor of complications and must be aggressively managed 2
• Do not delay catheter removal when complications arise—early removal prevents progression to major complications requiring surgical intervention 2
• Do not perform fluoroscopy-guided placement without abdominal shielding and minimized fluoroscopy time—fetal radiation exposure carries teratogenic risk 5